Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-GTase IgY is a passive immunization therapy developed by the Immunology Research Institute in Gifu for the prevention and treatment of dental caries (tooth decay). The drug consists of polyclonal immunoglobulin Y (IgY) antibodies extracted from the egg yolks of hens immunized against glucosyltransferase (GTase), an enzyme produced by *Streptococcus mutans*. GTase is critical for the synthesis of water-insoluble glucans, which facilitate the adhesion of bacteria to the tooth surface and the formation of dental plaque. By binding to and neutralizing GTase, these IgY antibodies inhibit bacterial colonization and the subsequent acid production that leads to enamel erosion. The product is often incorporated into oral care formulations such as lozenges, tablets, or functional food products to maintain dental health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anti-GTase IgY.